Quantcast
The Name Of A Drug Significantly Influences How The Patient

The Name Of A Drug Significantly Influences How The Patient Feels About The Treatment

Rayshell Clapper for redOrbit.com - Your Universe Online Many individuals rely on pharmacology for different physical or mental health issues. However, some conditions require certain pharmacology which can be described as used for something...

Latest Organofluorides Stories

2014-10-22 08:30:21

DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports for United States (US), China and Japan to the cancer drugs market research collection of its online library. The PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023...

2014-10-21 12:29:40

However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed oncologists in Argentina and Mexico are primarily prescribing biomarker-driven agents for the treatment of HER2-positive breast cancer and EGFR-mutation positive metastatic, non-small-cell lung cancer (NSCLC). However,...

2014-10-21 12:22:28

MORRIS TOWNSHIP, N.J., Oct. 21, 2014 /PRNewswire/ -- The allegations outlined in the Statement of Objections are baseless and conflict with the EU's own laws that encourage collaboration on development. Honeywell is confident that our practices are consistent with the law and that the Commission will conclude that we acted in full compliance with European Union competition rules. By collaborating on expensive and risky development, Honeywell and DuPont were able to develop HFO-1234yf...

2014-10-21 12:21:08

WILMINGTON, Del., Oct. 21, 2014 /PRNewswire/ -- Thierry F.J. Vanlancker, president, DuPont Chemicals & Fluoroproducts, said the following about the European Commission's Statement of Objections: "DuPont has complied at all times with applicable laws in its development and commercialization of HFO-1234yf, and we plan to defend vigorously against the Commission's allegations and preliminary conclusions. This is one step in a long process, and while it may take years to be resolved,...

2014-10-20 12:24:41

Company Expects New Family of Products will Reduce Greenhouse Gas Content of Refrigerants by 245 Million Tons CO2 Equivalent Worldwide by 2025 WILMINGTON, Del., Oct. 20, 2014 /PRNewswire/ -- DuPont Fluorochemicals (DuPont) today announced the introduction of three new refrigerants in its more sustainable DuPont(TM) Opteon® family. These refrigerants have far lower global warming potential (GWP) than the products they are designed to replace and will enable compliance with a growing...

2014-10-18 23:01:41

The Firm is representing numerous Risperdal lawsuit plaintiffs in claims that allege the atypical antipsychotic medication caused gynecomastia, or male breast growth. New York, New York (PRWEB) October 18, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, 888 product liability claims have been filed in...

2014-10-17 12:24:41

DUBLIN, October 17, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/f9njsq/micro_market) has announced the addition of the "Micro Market Monitor : North America Fluoropolymers Coating Additives Market" [http://www.researchandmarkets.com/research/f9njsq/micro_market ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Fluoropolymers Coating Additives-North American market was...

2014-10-16 12:28:14

Launch of Novel Immune Checkpoint Inhibitors Will Fuel Market Growth and Will Dramatically Enhance RCC Treatment Algorithm, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 16, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for renal cell carcinoma (RCC) therapies will grow to approximately $2.5 billion by 2023, despite the aggressive generic erosion of Pfizer's Sutent, GlaxoSmithKline's Votrient, Pfizer's Inlyta, Bayer HealthCare/Onyx...

2014-10-15 23:01:37

New research report “Global Cancer Kinase Inhibitors Market & Pipeline Insight” elaborated by Kuick Research is now available at MarketPublishers.com. According to the study, the global kinase inhibitors market is poised to gain momentum through 2018. London, UK (PRWEB) October 15, 2014 The field of cancer is developing driven primarily by the ageing world population, soaring rates of smoking, and the growth in obesity across all geographies. This opens up a slew of nice...

2014-10-15 12:31:56

NEW YORK, Oct. 15, 2014 /PRNewswire/ -- As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in U.S. courts, a hearing recently held in Vermont is raising serious questions about the adherence to pediatric dosing guidelines by doctors who prescribe antipsychotic drugs like Risperdal to children, Bernstein Liebhard LLP reports. According to Dr. David C. Rettew, Director of the Pediatric Psychiatry Clinic at University of Vermont's College of Medicine, a...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.